Javier Cortés, MD, PhD, on Clinical Interpretation: First-Line Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer

Posted: Wednesday, January 12, 2022

Javier Cortés, MD, PhD, of the International Breast Cancer Center, discusses how pembrolizumab might contribute to first-line treatment of patients with inoperable or metastatic triple-negative breast cancer and his recommendations for the best way to integrate this agent with chemotherapy in this cohort.